-
Bristol Myers Squibb: Phase III study CheckMate-8HW achieved one of the dual primary endpoints of progression free survival
On December 11th, Bristol Myers Squibb announced that the Phase III study CheckMate-8HW, a clinical study evaluating the combination of nivolumab and ipilimumab, compared the chemotherapy regimen cho ... -
Zaiding Pharmaceuticals acquires the domestic sales rights of PD-1 from Baishi Meishi Squibb
On February 23rd, Interface News learned that multinational pharmaceutical company (MNC), Bristol Myers Squibb (BMS), has granted the sales rights of its star product, Navolizumab (commonly known as ... -
Baishi Meishi Guibao's US stock rose more than 5% before trading
According to the AI news, the US stock market of Bristol Myers Squibb rose more than 5% before trading. The US regulatory authorities approved its Cobenfy for the treatment of schizophrenia, which is ... -
Baishi Meishi Guibao's US stock rose more than 5% before trading
On September 27th, the US stock market of Bristol Myers Squibb rose more than 5% before trading, as US regulatory authorities approved its Cobenfy for the treatment of schizophrenia, the first drug a ...